{"id":939360,"date":"2026-02-24T08:23:32","date_gmt":"2026-02-24T13:23:32","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/helus-pharma-appoints-former-pfizer-chief-medical-officer-dr-freda-lewis-hall-to-board-of-directors-chair-of-the-scientific-advisory-committee\/"},"modified":"2026-02-24T08:23:32","modified_gmt":"2026-02-24T13:23:32","slug":"helus-pharma-appoints-former-pfizer-chief-medical-officer-dr-freda-lewis-hall-to-board-of-directors-chair-of-the-scientific-advisory-committee","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/helus-pharma-appoints-former-pfizer-chief-medical-officer-dr-freda-lewis-hall-to-board-of-directors-chair-of-the-scientific-advisory-committee\/","title":{"rendered":"Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors &amp; Chair of the Scientific Advisory Committee"},"content":{"rendered":"<div class=\"mw_release\">\n<ul>\n<li style=\"text-align:justify\">\n          <em>In this role, Dr. Lewis-Hall will guide clinical development strategy, regulatory engagement, and translational rigor across Helus\u2019 novel serotonergic agonist (\u201cNSA\u201d) portfolio<\/p>\n<p><\/em>\n        <\/li>\n<\/ul>\n<p align=\"justify\">\n        <em>This news release constitutes a \u201cdesignated news release\u201d for the purpose of the Company\u2019s prospectus supplement dated December 30, 2025, to it short form base shelf prospectus dated September 17, 2025, as amended on December 19, 2025.<\/em>\n      <\/p>\n<p align=\"justify\">NEW YORK and TORONTO, Feb.  24, 2026  (GLOBE NEWSWIRE) &#8212; Helus Pharma\u2122 (Nasdaq: HELP) (Cboe CA: HELP), a clinical stage pharmaceutical company developing NSAs for serious mental health conditions, today announced the appointment of Dr. Freda Lewis-Hall, DFAPA, MFPM, to its Board of Directors. Dr. Lewis-Hall will also serve as Chair of the Company\u2019s Scientific Advisory Committee.<\/p>\n<p align=\"justify\">Dr. Lewis-Hall is a pioneering physician and biopharmaceutical executive with more than 40 years of experience spanning clinical care, research, academia, corporate leadership, and public health advocacy. She began her medical career as a practicing psychiatrist, focusing on the impact of mental illness on families and communities.<\/p>\n<p align=\"justify\">She later held senior leadership roles across the biopharmaceutical industry, including serving for more than a decade on Pfizer\u2019s Executive Leadership Team as Executive Vice President and Chief Medical Officer. In that role, she led a global medical organization operating in more than 125 countries and supporting a broad portfolio of medicines and vaccines. She subsequently served as Chief Patient Officer, advancing patient engagement, inclusion, and health equity initiatives across the enterprise. During her tenure, she also helped lead the spinout of SpringWorks Therapeutics and served on its Board of Directors, guiding the company through regulatory approvals and its evolution into a commercial-stage organization prior to its acquisition by Merck KGaA for approximately $3.4 billion. Dr. Lewis-Hall has also held senior leadership positions at Vertex Pharmaceuticals, Bristol Myers Squibb, Pharmacia Corporation, and Eli Lilly and Company.<\/p>\n<p align=\"justify\">Dr. Lewis-Hall is a Distinguished Fellow of the American Psychiatric Association and previously served as Vice Chairperson and Associate Professor in the Department of Psychiatry at Howard University College of Medicine. She has also advised the National Institute of Mental Health.<\/p>\n<p align=\"justify\">\u201cDr. Lewis-Hall is a highly respected physician and leader whose career has been defined by bringing complex, innovative therapies from development to patients around the world, particularly in areas of serious and underserved mental health need,\u201d said Michael Cola, Chief Executive Officer of the Company. \u201cHer deep experience in clinical strategy, regulatory engagement, and global commercialization will be invaluable as we advance our novel serotonergic agonist programs for psychiatric disorders and continue building a company grounded in scientific rigor, patient impact, and responsible scale. We are honored to welcome her to our Board and as Chair overseeing the Scientific Advisory Committee.\u201d<\/p>\n<p align=\"justify\">\u201cThroughout my career, I have focused on ensuring that scientific innovation translates into therapies that make a meaningful difference for patients \u2014 and that can be delivered reliably within real-world healthcare systems,\u201d said Dr. Lewis-Hall. \u201cWhat distinguishes Helus Pharma is its disciplined approach at the intersection of rigorous science, a thoughtfully advancing clinical portfolio, and focused execution in areas of significant unmet need in mental health. I believe the company is building a differentiated development platform that has yet to be fully recognized by the broader market.\u201d<\/p>\n<p align=\"justify\">She continues, \u201cHelus Pharma\u2019s commitment to strong clinical design, reproducibility, and regulatory clarity reflects the standards required to earn and sustain trust among patients, providers, and regulators. This work is deeply personal to me, given my early experience on the frontlines of mental health care. I look forward to supporting the company as it advances programs designed to deliver meaningful, durable outcomes for patients and long-term value for stakeholders.\u201d<\/p>\n<p align=\"justify\">As Chair of the Scientific Advisory Committee, Dr. Lewis-Hall will provide leadership in scientific, clinical, and regulatory governance across Helus\u2019 portfolio, advising on discovery opportunities, clinical development strategy, and regulatory pathways to support pipeline advancement and progress toward commercialization.<\/p>\n<p align=\"justify\">As a member of the Board of Directors, she will contribute to corporate governance and long-term strategic oversight, helping ensure that patient outcomes, clinical rigor, and disciplined decision-making remain central to the Company\u2019s growth strategy.<\/p>\n<p align=\"justify\">Dr. Lewis-Hall\u2019s appointment to the Company\u2019s board of directors is subject to approval of Cboe Canada.<\/p>\n<p align=\"justify\">\n        <strong>About Helus Pharma<\/strong>\n      <\/p>\n<p align=\"justify\">Helus Pharma\u2122, the commercial operating name of Cybin Inc. (the \u201cCompany\u201d or \u201cHelus Pharma\u201d) is a clinical stage pharmaceutical company committed to helping minds heal by developing proprietary NSAs &#8211; novel serotonergic agonists: synthetic molecules designed to activate serotonin pathways that are believed to promote neuroplasticity. The Company\u2019s proprietary NSAs are intended to address the large unmet need for people who suffer from depression, anxiety, and other mental health conditions.<\/p>\n<p align=\"justify\">With class leading data, Helus Pharma aims to improve the treatment landscape through the introduction of NSAs that aim to provide durable improvements in mental health. Helus Pharma is currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of major depressive disorder that has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration and HLP004, also a proprietary NSA in Phase 2 for generalized anxiety disorder. Additionally, Helus Pharma has an extensive research portfolio of investigational NSAs.<\/p>\n<p align=\"justify\">The Company operates in Canada, the United States, the United Kingdom, and Ireland. For Company updates and to learn more about Helus Pharma, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=UpYQ8FALgm3r_m560V4ttXF5miPKPBfza8QY8L75Bs5UG0hEQNum85ztrB1LT0KDWeNI2YzLp-jQcVsYm4u8Kg==\" rel=\"nofollow\" target=\"_blank\">www.helus.com<\/a> or follow the team on X, LinkedIn, YouTube and Instagram. Helus Pharma<sup>TM<\/sup> is a trademark of Cybin Corp.<\/p>\n<p align=\"justify\">\n        <strong>Cautionary Notes and Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">Certain statements in this news release relating to the Company are forward-looking statements or forward-looking information within the meaning of applicable securities laws (collectively, \u201cforward-looking statements\u201d) and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as \u201cmay\u201d, \u201cshould\u201d, \u201ccould\u201d, \u201cpotential\u201d, \u201cpossible\u201d, \u201cintend\u201d, \u201cestimate\u201d, \u201cplan\u201d, \u201canticipate\u201d, \u201cexpect\u201d, \u201cbelieve\u201d or \u201ccontinue\u201d, or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the impact of Freda Lewis-Hall on the Scientific Advisory Committee and Board of Directors, and the Company\u2019s plans to engineer proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health conditions.<\/p>\n<p align=\"justify\">These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the NSA market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; implications of disease outbreaks on the Company&#8217;s operations; and the risk factors set out in each of the Company&#8217;s management&#8217;s discussion and analysis for the three and nine month periods ended December 31, 2025, and the Company\u2019s annual information form for the year ended March 31, 2025, which are available under the Company&#8217;s profile on SEDAR+ at www.sedarplus.ca and with the U.S. Securities and Exchange Commission on EDGAR at www.sec.gov\/edgar. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.<\/p>\n<p align=\"justify\">The Company makes no medical, treatment or health benefit claims about the Company\u2019s proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding NSAs or HLP003, HLP004 and other programs of the Company. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of NSAs, HLP003, HLP004 or other programs of the Company can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. If Helus Pharma cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the Company\u2019s performance and operations.<\/p>\n<p align=\"justify\">\n        <em>Neither Cboe Canada, nor the Nasdaq Global Market stock exchange, have approved or disapproved the contents of this news release and are not responsible for the adequacy and accuracy of the contents herein. <\/em>\n      <\/p>\n<p align=\"justify\">\n        <strong>Investor Contact:<\/strong><br \/>\n        <br \/>Josh Barer<br \/>astr partners<br \/>Managing Director<br \/>(908) 578-6478<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=P2Xa7LCBrxHNST6o9obyw7YMdrdVzSHZTKgiXkkQ0Y3r2WRELdPMjYKX5p9_XAUHaQ4V-Hj5CAQyfbVRiXvIjqgAZRKkW3elGRCLu2Ken9yhT8LRZJTIqcQCn7-8KRvr\" rel=\"nofollow\" target=\"_blank\">josh.barer@astrpartners.com<\/a><\/p>\n<p align=\"justify\">George Tziras<br \/>Chief Business Officer<br \/>Helus Pharma<br \/>1-866-292-4601<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=jqweb_6O1TeHvfBgUNfZ-2XscV_-iWfOlijHYulTBO1Jx2bE5dUASXEKLI-e8pEqmmWBe8WIhZQLkJeXAUFk9SZFrKYFFZUY4GcQztB5xlQ=\" rel=\"nofollow\" target=\"_blank\">irteam@helus.com<\/a> \u2013 or \u2013 <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=U6_4s5avxrpwPIoM80ZRRmASabMmf8GUnqbllq-wXyfZbrqmSkt8oNA_I9JwLtpHXDfT5iHJVpza0rRQ6E3ZJ3lF2t1T7ezYuSXL94N4gP0=\" rel=\"nofollow\" target=\"_blank\">media@helus.com<\/a><\/p>\n<p align=\"justify\">\n        <strong>Media Contact:<\/strong><br \/>\n        <br \/>Johnny Tokarczyk<br \/>RXMD<br \/>Public Relations Director<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=N_Dbi94kgkvoNjH2Do7S4tU45BVUowEVwww5KLo-dwHk3ZlMhhpS65yoSpym7aPecOg25AOaewYtPZAP870kJtcle2vU1ay-Mre8_zDk0yY=\" rel=\"nofollow\" target=\"_blank\">jtokarczyk@rxmedyn.com<\/a><br \/>(914) 772-7562<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1OTg4NSM3NDUwOTQ4IzIyMjIzNTA=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NjFlMmQ3MTAtOGNjOS00YWQ0LTlhODUtZmYzYTljMzhkM2E0LTEyMzM5MDMtMjAyNi0wMi0yNC1lbg==\/tiny\/Helus-Pharma.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>In this role, Dr. Lewis-Hall will guide clinical development strategy, regulatory engagement, and translational rigor across Helus\u2019 novel serotonergic agonist (\u201cNSA\u201d) portfolio This news release constitutes a \u201cdesignated news release\u201d for the purpose of the Company\u2019s prospectus supplement dated December 30, 2025, to it short form base shelf prospectus dated September 17, 2025, as amended on December 19, 2025. NEW YORK and TORONTO, Feb. 24, 2026 (GLOBE NEWSWIRE) &#8212; Helus Pharma\u2122 (Nasdaq: HELP) (Cboe CA: HELP), a clinical stage pharmaceutical company developing NSAs for serious mental health conditions, today announced the appointment of Dr. Freda Lewis-Hall, DFAPA, MFPM, to its Board of Directors. Dr. Lewis-Hall will also serve as Chair of the Company\u2019s Scientific Advisory Committee. Dr. Lewis-Hall is a &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/helus-pharma-appoints-former-pfizer-chief-medical-officer-dr-freda-lewis-hall-to-board-of-directors-chair-of-the-scientific-advisory-committee\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors &amp; Chair of the Scientific Advisory Committee&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-939360","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors &amp; Chair of the Scientific Advisory Committee - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/helus-pharma-appoints-former-pfizer-chief-medical-officer-dr-freda-lewis-hall-to-board-of-directors-chair-of-the-scientific-advisory-committee\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors &amp; Chair of the Scientific Advisory Committee - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"In this role, Dr. Lewis-Hall will guide clinical development strategy, regulatory engagement, and translational rigor across Helus\u2019 novel serotonergic agonist (\u201cNSA\u201d) portfolio This news release constitutes a \u201cdesignated news release\u201d for the purpose of the Company\u2019s prospectus supplement dated December 30, 2025, to it short form base shelf prospectus dated September 17, 2025, as amended on December 19, 2025. NEW YORK and TORONTO, Feb. 24, 2026 (GLOBE NEWSWIRE) &#8212; Helus Pharma\u2122 (Nasdaq: HELP) (Cboe CA: HELP), a clinical stage pharmaceutical company developing NSAs for serious mental health conditions, today announced the appointment of Dr. Freda Lewis-Hall, DFAPA, MFPM, to its Board of Directors. Dr. Lewis-Hall will also serve as Chair of the Company\u2019s Scientific Advisory Committee. Dr. Lewis-Hall is a &hellip; Continue reading &quot;Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors &amp; Chair of the Scientific Advisory Committee&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/helus-pharma-appoints-former-pfizer-chief-medical-officer-dr-freda-lewis-hall-to-board-of-directors-chair-of-the-scientific-advisory-committee\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-24T13:23:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1OTg4NSM3NDUwOTQ4IzIyMjIzNTA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/helus-pharma-appoints-former-pfizer-chief-medical-officer-dr-freda-lewis-hall-to-board-of-directors-chair-of-the-scientific-advisory-committee\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/helus-pharma-appoints-former-pfizer-chief-medical-officer-dr-freda-lewis-hall-to-board-of-directors-chair-of-the-scientific-advisory-committee\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors &amp; Chair of the Scientific Advisory Committee\",\"datePublished\":\"2026-02-24T13:23:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/helus-pharma-appoints-former-pfizer-chief-medical-officer-dr-freda-lewis-hall-to-board-of-directors-chair-of-the-scientific-advisory-committee\\\/\"},\"wordCount\":1561,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/helus-pharma-appoints-former-pfizer-chief-medical-officer-dr-freda-lewis-hall-to-board-of-directors-chair-of-the-scientific-advisory-committee\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1OTg4NSM3NDUwOTQ4IzIyMjIzNTA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/helus-pharma-appoints-former-pfizer-chief-medical-officer-dr-freda-lewis-hall-to-board-of-directors-chair-of-the-scientific-advisory-committee\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/helus-pharma-appoints-former-pfizer-chief-medical-officer-dr-freda-lewis-hall-to-board-of-directors-chair-of-the-scientific-advisory-committee\\\/\",\"name\":\"Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors &amp; Chair of the Scientific Advisory Committee - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/helus-pharma-appoints-former-pfizer-chief-medical-officer-dr-freda-lewis-hall-to-board-of-directors-chair-of-the-scientific-advisory-committee\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/helus-pharma-appoints-former-pfizer-chief-medical-officer-dr-freda-lewis-hall-to-board-of-directors-chair-of-the-scientific-advisory-committee\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1OTg4NSM3NDUwOTQ4IzIyMjIzNTA=\",\"datePublished\":\"2026-02-24T13:23:32+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/helus-pharma-appoints-former-pfizer-chief-medical-officer-dr-freda-lewis-hall-to-board-of-directors-chair-of-the-scientific-advisory-committee\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/helus-pharma-appoints-former-pfizer-chief-medical-officer-dr-freda-lewis-hall-to-board-of-directors-chair-of-the-scientific-advisory-committee\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/helus-pharma-appoints-former-pfizer-chief-medical-officer-dr-freda-lewis-hall-to-board-of-directors-chair-of-the-scientific-advisory-committee\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1OTg4NSM3NDUwOTQ4IzIyMjIzNTA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1OTg4NSM3NDUwOTQ4IzIyMjIzNTA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/helus-pharma-appoints-former-pfizer-chief-medical-officer-dr-freda-lewis-hall-to-board-of-directors-chair-of-the-scientific-advisory-committee\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors &amp; Chair of the Scientific Advisory Committee\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors &amp; Chair of the Scientific Advisory Committee - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/helus-pharma-appoints-former-pfizer-chief-medical-officer-dr-freda-lewis-hall-to-board-of-directors-chair-of-the-scientific-advisory-committee\/","og_locale":"en_US","og_type":"article","og_title":"Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors &amp; Chair of the Scientific Advisory Committee - Market Newsdesk","og_description":"In this role, Dr. Lewis-Hall will guide clinical development strategy, regulatory engagement, and translational rigor across Helus\u2019 novel serotonergic agonist (\u201cNSA\u201d) portfolio This news release constitutes a \u201cdesignated news release\u201d for the purpose of the Company\u2019s prospectus supplement dated December 30, 2025, to it short form base shelf prospectus dated September 17, 2025, as amended on December 19, 2025. NEW YORK and TORONTO, Feb. 24, 2026 (GLOBE NEWSWIRE) &#8212; Helus Pharma\u2122 (Nasdaq: HELP) (Cboe CA: HELP), a clinical stage pharmaceutical company developing NSAs for serious mental health conditions, today announced the appointment of Dr. Freda Lewis-Hall, DFAPA, MFPM, to its Board of Directors. Dr. Lewis-Hall will also serve as Chair of the Company\u2019s Scientific Advisory Committee. Dr. Lewis-Hall is a &hellip; Continue reading \"Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors &amp; Chair of the Scientific Advisory Committee\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/helus-pharma-appoints-former-pfizer-chief-medical-officer-dr-freda-lewis-hall-to-board-of-directors-chair-of-the-scientific-advisory-committee\/","og_site_name":"Market Newsdesk","article_published_time":"2026-02-24T13:23:32+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1OTg4NSM3NDUwOTQ4IzIyMjIzNTA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/helus-pharma-appoints-former-pfizer-chief-medical-officer-dr-freda-lewis-hall-to-board-of-directors-chair-of-the-scientific-advisory-committee\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/helus-pharma-appoints-former-pfizer-chief-medical-officer-dr-freda-lewis-hall-to-board-of-directors-chair-of-the-scientific-advisory-committee\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors &amp; Chair of the Scientific Advisory Committee","datePublished":"2026-02-24T13:23:32+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/helus-pharma-appoints-former-pfizer-chief-medical-officer-dr-freda-lewis-hall-to-board-of-directors-chair-of-the-scientific-advisory-committee\/"},"wordCount":1561,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/helus-pharma-appoints-former-pfizer-chief-medical-officer-dr-freda-lewis-hall-to-board-of-directors-chair-of-the-scientific-advisory-committee\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1OTg4NSM3NDUwOTQ4IzIyMjIzNTA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/helus-pharma-appoints-former-pfizer-chief-medical-officer-dr-freda-lewis-hall-to-board-of-directors-chair-of-the-scientific-advisory-committee\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/helus-pharma-appoints-former-pfizer-chief-medical-officer-dr-freda-lewis-hall-to-board-of-directors-chair-of-the-scientific-advisory-committee\/","name":"Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors &amp; Chair of the Scientific Advisory Committee - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/helus-pharma-appoints-former-pfizer-chief-medical-officer-dr-freda-lewis-hall-to-board-of-directors-chair-of-the-scientific-advisory-committee\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/helus-pharma-appoints-former-pfizer-chief-medical-officer-dr-freda-lewis-hall-to-board-of-directors-chair-of-the-scientific-advisory-committee\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1OTg4NSM3NDUwOTQ4IzIyMjIzNTA=","datePublished":"2026-02-24T13:23:32+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/helus-pharma-appoints-former-pfizer-chief-medical-officer-dr-freda-lewis-hall-to-board-of-directors-chair-of-the-scientific-advisory-committee\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/helus-pharma-appoints-former-pfizer-chief-medical-officer-dr-freda-lewis-hall-to-board-of-directors-chair-of-the-scientific-advisory-committee\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/helus-pharma-appoints-former-pfizer-chief-medical-officer-dr-freda-lewis-hall-to-board-of-directors-chair-of-the-scientific-advisory-committee\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1OTg4NSM3NDUwOTQ4IzIyMjIzNTA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1OTg4NSM3NDUwOTQ4IzIyMjIzNTA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/helus-pharma-appoints-former-pfizer-chief-medical-officer-dr-freda-lewis-hall-to-board-of-directors-chair-of-the-scientific-advisory-committee\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors &amp; Chair of the Scientific Advisory Committee"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/939360","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=939360"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/939360\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=939360"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=939360"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=939360"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}